NCT01401244View on ClinicalTrials.gov

Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 14, 2011

Primary Completion Date

September 27, 2011

Study Completion Date

September 27, 2011

Conditions
Genetic DisorderPrader-Willi SyndromeGrowth DisorderIdiopathic Short StatureHealthy
Interventions
DRUG

somatropin

A single dose 4.0 mg administered subcutaneously (under the skin) via Norditropin® FlexPro® pen

DRUG

somatropin

A single dose 4.0 mg administered subcutaneously (under the skin) via Genotropin® Pen 12

Trial Locations (1)

47710

Novo Nordisk Investigational Site, Evansville

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY